/AYTU

AYTU Stock - Aytu BioPharma, Inc.

Q: What is the analyst price target for AYTU?

Analyst price target information is not currently available for AYTU.

Q: What is AYTU's market cap?

Market capitalization information is not currently available for AYTU.

Healthcare|Drug Manufacturers - Specialty & Generic|NASDAQ

$2.55+3.24%

+$0.08 (+3.24%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $2.81

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for AYTU

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.29

52W High$2.82

52W Low$0.95

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$66.38M	$65.18M	$107.40M	$96.67M	$65.63M
Gross Profit	$45.83M	$49.05M	$66.63M	$50.28M	$29.20M
Gross Margin	69.0%	75.3%	62.0%	52.0%	44.5%
Operating Income	$-7,827,000	$-1,591,000	$-17,065,000	$-109,906,000	$-58,870,000
Net Income	$-13,562,000	$-15,844,000	$-17,051,000	$-108,779,000	$-58,289,000
Net Margin	-20.4%	-24.3%	-15.9%	-112.5%	-88.8%
EPS	$-2.16	$-2.86	$-5.11	$-74.01	$-69.60

Company Overview

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

2 Bullish0 Neutral/Bearish

Price Targets

$10

Average Target

↑ 292.2% Upside

Now

Low

$10

Average

$12

High

Based on 2 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
July 1st 2025	Lake Street	Initiation	Buy	$8
June 30th 2025	Ascendiant Capital Markets	Initiation	Buy	$12

Earnings History & Surprises

AYTU

Beat Rate

39%

Last 18 quarters

Avg Surprise

-320.4%

EPS vs Estimate

Beats / Misses

7/10

1 met exactly

Latest EPS

$-0.08

Q4 2025

EPS Surprise History

Q1 24

+84.0%

$-0.04vs$-0.25

Q2 24

+18.8%

$-0.52vs$-0.64

Q3 24

-82.2%

$-0.82vs$-0.45

Q4 24

+41.2%

$-0.20vs$-0.34

Q1 25

0.0%

$-0.28vs$-0.28

Q2 25

+217.6%

$0.20vs$-0.17

Q3 25

-1200.0%

$-0.26vs$-0.02

Q4 25

-33.3%

$-0.08vs$-0.06

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 12, 2026	—	—	—	—
Q1 2026	Feb 11, 2026	$-0.24	—	—	—
Q4 2025	Nov 13, 2025	$-0.06	$-0.08	-33.3%	✗ MISS
Q3 2025	Sep 23, 2025	$-0.02	$-0.26	-1200.0%	✗ MISS
Q2 2025	May 14, 2025	$-0.17	$0.20	+217.6%	✓ BEAT
Q1 2025	Feb 12, 2025	$-0.28	$-0.28	0.0%	= MET
Q4 2024	Nov 13, 2024	$-0.34	$-0.20	+41.2%	✓ BEAT
Q3 2024	Sep 26, 2024	$-0.45	$-0.82	-82.2%	✗ MISS
Q2 2024	May 15, 2024	$-0.64	$-0.52	+18.8%	✓ BEAT
Q1 2024	Feb 14, 2024	$-0.25	$-0.04	+84.0%	✓ BEAT
Q4 2023	Nov 14, 2023	$-0.04	$-1.48	-3600.0%	✗ MISS
Q3 2023	Sep 27, 2023	$-0.95	$0.16	+116.8%	✓ BEAT
Q2 2023	May 11, 2023	$-0.63	$-1.93	-206.3%	✗ MISS
Q1 2023	Feb 21, 2023	$0.20	$-1.31	-755.0%	✗ MISS
Q4 2022	Nov 14, 2022	$-3.60	$-1.20	+66.7%	✓ BEAT
Q3 2022	Sep 27, 2022	$-4.80	$-5.00	-4.2%	✗ MISS
Q2 2022	May 16, 2022	$-8.20	$-5.40	+34.1%	✓ BEAT
Q1 2022	Feb 14, 2022	$-7.09	$-8.80	-24.1%	✗ MISS
Q4 2021	Nov 15, 2021	$-2.97	$-6.60	-122.4%	✗ MISS
Q3 2021	Sep 27, 2021	$-3.20	$-13.40	-318.7%	✗ MISS

Frequently Asked Questions about AYTU

What is AYTU's current stock price?

Aytu BioPharma, Inc. (AYTU) is currently trading at $2.55 per share. The stock has moved +3.24% today.

What is the analyst price target for AYTU?

No analyst price targets are currently available for this stock.

What sector is Aytu BioPharma, Inc. in?

Aytu BioPharma, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.

What is AYTU's market cap?

Aytu BioPharma, Inc. has a market capitalization of $0.02 billion, making it a small-cap company.

Does AYTU pay dividends?

No, Aytu BioPharma, Inc. does not currently pay a dividend to shareholders.